Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)Helena A. Yu, Jonathan W. Riess, Xiuning Le et al.|Clinical Lung Cancer|2021Cited by 73